Another plus was pricing visibility
Achieving over 10% weight loss is associated with clinically significant reductions in risk of chronic conditions such as type 2 diabetes and heart disease
Blue Shield of California 2025 GLP-1 policy Kaiser Northwest requires a failed adequate trial of at least 3 months of Ozempic (semaglutide for diabetes/CV) before authorizing Wegovy for weight-loss an unusual intra-molecule step-therapy requirement not found at most commercial plans
For example, combining semaglutide with other GLP-1 agonists or certain diabetic medicines without medical supervision can be unsafe
In practice, this means filling roughly half your plate with vegetables, a quarter with protein (chicken, fish, eggs, beans, lentils, tofu, or Greek yoghurt), and a quarter with complex carbohydrates (wholegrain bread, brown rice, oats, potatoes, or quinoa)